CoChat

Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials

Open access
De Giorgi, Riccardo, De Crescenzo, Franco, Rizzo Pesci, Nicola, Martens, Marieke, Howard, Wendy, Cowen, Philip J., Harmer, Catherine J. · 2021 · PLOS ONE

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Background: The burden of depressive disorder is large and new treatment approaches are required. Repurposing widely available drugs such as statins may be a time- and cost-effective solution. Statins have anti-inflammatory and anti-oxidant properties which have been shown to be relevant to the pathophysiology of depression. This study assesses the efficacy, acceptability, tolerability, and safety of statins in major depressive disorder. Methods: Our study is an update and extension of a previous meta-analysis published in 2016 by Salagre et al. We performed a systematic review (PubMed/MEDLINE, Cochrane CENTRAL, ISI Web of Science, CINAHL, and ClinicalTrials.gov until the 1 st September 2020) and meta-analysis of randomized controlled trials using any statin against placebo or any other statin in the treatment of major depressive disorder. Our primary efficacy outcome measure was the mean value on any standardized scale for depressive symptoms at 8 weeks of treatment. We also calculated outcomes for efficacy, response, and remission at 2, 4, and 12 weeks, as well as acceptability (dropouts for any cause), tolerability (dropouts due to any adverse event), and safety (any adverse event) outcomes at the studies’ endpoints. Furthermore, we conducted an exploratory network meta-analysis for the primary efficacy outcome to identify potential differences between statins. Results: We retrieved five randomized controlled trials meeting our inclusion criteria: four used a statin in addition to an antidepressant and compared it to placebo plus antidepressant, and one compared two statins alone. and one comparing one statin with another. Statins compared to placebo in addition to antidepressants were efficacious at 8 weeks (N = 255, SMD = -0.48, 95% CI = -0.74 to -0. 22) and 12 weeks (N = 134, SMD = -0.47, 95% CI = -0.89 to -0.05, moderate certainty) with no difference for acceptability, tolerability, and safety (low certainty). An exploratory network meta-analysis suggested that the most lipophilic statins, especially simvastatin, could be more efficacious than less lipophilic or hydrophilic molecules. Conclusions: This systematic review suggests the efficacy, acceptability, tolerability, and safety of statins in addition to antidepressants in patients with major depressive disorder. Further clinical trials in different settings are required to test this result. Trial rgistration: PROSPERO registration: CRD42020170938.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0249409

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Main statins’ lipophilicity. Lipophilicity is measured as C log P octanol/water, i.e. higher values correspond to higher lipophilicity. Note that simvastatin, lovastatin, and atorvastatin [29] are considered lipophilic statins, whereas rosuvastatin [30] is a highly hydrophilic statin.
Fig 1 Main statins’ lipophilicity. Lipophilicity is measured as C log P octanol/water, i.e. higher values correspond to higher lipophilicity. Note that simvastatin, lovastatin, and atorvastatin [29] are considered lipophilic statins, whereas rosuvastatin [30] is a highly hydrophilic statin.CC BY · PubMed Central
Fig 2 PRISMA flow chart.
Fig 2 PRISMA flow chart.CC BY · PubMed Central
Fig 3 Forest plot for efficacy as mean value for depressive symptoms.
Fig 3 Forest plot for efficacy as mean value for depressive symptoms.CC BY · PubMed Central
Fig 4 Forest plot for acceptability (number of participants discontinuing treatment [dropouts] due to any cause) and for tolerability (number of participants discontinuing treatment [dropouts] due to adverse events).
Fig 4 Forest plot for acceptability (number of participants discontinuing treatment [dropouts] due to any cause) and for tolerability (number of participants discontinuing treatment [dropouts] due to adverse events).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. C. National Clinical Guideline, National Institute for Health and Clinical Excellence: Guidance. Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease.

Cited by

See all 54

Metadata

Authors
De Giorgi, R., De Crescenzo, F., Rizzo Pesci, N., Martens, M., Howard, W., Cowen, P. J., & Harmer, C. J.
Affiliations
  • Warneford Hospital (GB)
  • Oxford Health NHS Foundation Trust (GB)
Venue
PLOS ONE
Published
2021-03-30
Volume
16
Issue
3
Pages
e0249409
ISSN
1932-6203 (ISSN-L)
OpenAlex
W3145353625
Cited by
52
References
50
Citations by year
2026: 3 · 2025: 12 · 2024: 6 · 2023: 14 · 2022: 12 · 2021: 5
FWCI
1.17
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Wellcome Trust (102176/Z/13/Z; grant: 216452/Z/19/Z)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
statins, major depressive disorder, drug repurposing, antidepressant augmentation, simvastatin, lipophilicity, depressive symptoms, treatment response and remission, safety and tolerability, anti-inflammatory effects of statins, adverse events, dropout rates, placebo comparison
MeSH terms
Antidepressive Agents, Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.